The solitary versus supported experience: Care inequality between rare and common cancer patients

Eline de Heus, Kalinka van de Camp, Esmee Driehuis, Jan Maarten van der Zwan, Carla M. L. van Herpen, Matthias A. W. Merkx, Saskia F. A. Duijts

Research output: Contribution to journalArticleAcademicpeer-review

1 Citation (Scopus)

Abstract

Objective: Patients with a rare cancer (RC) often have a more complex disease trajectory than patients with a common cancer. Research involving both patient groups is needed to identify differences and resemblances. In this study, we aimed to explore and compare experiences, needs and quality of life of patients with rare and common cancer throughout the disease trajectory. Methods: A qualitative focus group study was conducted, including patients with rare and common cancer (n = 25). Participants were purposively selected to reflect heterogeneity of cancer types. A semi-structured topic list was used. Focus groups (n = 4) were recorded, transcribed verbatim and analysed, using thematic analysis. Results: Three themes were identified emphasizing care inequality between patients with rare and common cancer: (1) The solitary experience: lack of information and support impact the RC patient, (2) Sudden impact, but recognition reduces the common cancer burden, and (3) Absence of psychosocial care requires being empowered as a cancer patient. Conclusions: Patients with RC are faced with enormous challenges due to the high impact of their solitary experience on their quality of life, while patients with common cancer generally experience social support and recognition alleviating their burden. Centralisation of care for patients with RC is needed and tailored psychosocial care should be provided to overcome inequalities.
Original languageEnglish
Pages (from-to)1667-1674
Number of pages8
JournalPsycho-Oncology
Volume32
Issue number11
Early online date2023
DOIs
Publication statusPublished - Nov 2023

Keywords

  • cancer
  • focus groups
  • oncology
  • patient experience
  • qualitative research
  • quality of life
  • rare cancer

Cite this